GlaxoSmithKline plc (LON:GSK) Receives Buy Rating from Berenberg Bank
Berenberg Bank reaffirmed their buy rating on shares of GlaxoSmithKline plc (LON:GSK) in a research report released on Wednesday morning. The firm currently has a GBX 1,885 ($24.56) price objective on the stock.
Other analysts have also recently issued research reports about the stock. UBS AG set a GBX 1,600 ($20.84) target price on shares of GlaxoSmithKline plc and gave the stock a neutral rating in a research note on Thursday, April 27th. Goldman Sachs Group, Inc. (The) restated a buy rating and issued a GBX 1,900 ($24.75) target price on shares of GlaxoSmithKline plc in a research note on Wednesday, May 31st. Bryan, Garnier & Co restated a buy rating and issued a GBX 1,750 ($22.80) target price on shares of GlaxoSmithKline plc in a research note on Wednesday, May 31st. Liberum Capital restated a buy rating and issued a GBX 1,900 ($24.75) target price on shares of GlaxoSmithKline plc in a research note on Wednesday, June 14th. Finally, Deutsche Bank AG restated a hold rating and issued a GBX 1,720 ($22.41) target price on shares of GlaxoSmithKline plc in a research note on Friday, June 30th. Four analysts have rated the stock with a sell rating, eleven have issued a hold rating and eight have assigned a buy rating to the stock. The company currently has a consensus rating of Hold and a consensus target price of GBX 1,734.73 ($22.60).
GlaxoSmithKline plc (LON GSK) opened at 1518.50 on Wednesday. GlaxoSmithKline plc has a 12 month low of GBX 1,446.50 and a 12 month high of GBX 1,745.56. The firm’s market cap is GBX 74.22 billion. The firm has a 50 day moving average of GBX 1,638.77 and a 200-day moving average of GBX 1,627.17.
ILLEGAL ACTIVITY WARNING: This news story was originally posted by Watch List News and is owned by of Watch List News. If you are viewing this news story on another website, it was illegally stolen and republished in violation of US & international copyright & trademark legislation. The original version of this news story can be viewed at https://www.watchlistnews.com/glaxosmithkline-plc-longsk-receives-buy-rating-from-berenberg-bank/1462133.html.
The firm also recently announced a dividend, which will be paid on Thursday, October 12th. Shareholders of record on Thursday, August 10th will be given a dividend of GBX 19 ($0.25) per share. This represents a yield of 1.23%. The ex-dividend date of this dividend is Thursday, August 10th.
In other news, insider Manvinder Singh Banga purchased 2,267 shares of the stock in a transaction dated Wednesday, July 26th. The stock was acquired at an average cost of GBX 1,599 ($20.83) per share, for a total transaction of £36,249.33 ($47,224.24). Also, insider Patrick Vallance purchased 861 shares of the stock in a transaction dated Friday, July 14th. The shares were purchased at an average price of GBX 1,618 ($21.08) per share, with a total value of £13,930.98 ($18,148.75). Over the last quarter, insiders have bought 3,150 shares of company stock valued at $5,054,075.
About GlaxoSmithKline plc
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Receive News & Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related companies with Analyst Ratings Network's FREE daily email newsletter.